Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products in China and internationally. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infe… Read more
Cisen Pharmaceutical Co Ltd (603367) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.43 Billion CNY
Based on the latest financial reports, Cisen Pharmaceutical Co Ltd (603367) has total liabilities worth CN¥1.43 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cisen Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Cisen Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cisen Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Cisen Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Unifull Industrial Fibre Co Ltd
SHE:002427
|
China | CN¥1.52 Billion |
|
Drägerwerk AG & Co. KGaA
PINK:DGWPF
|
USA | $1.52 Billion |
|
Hanwang Technology Co Ltd
SHE:002362
|
China | CN¥729.61 Million |
|
Topdanmark AS
PINK:TPDKY
|
USA | $18.45 Billion |
|
NORMA Group SE
OTCGREY:NOEJF
|
USA | $705.20 Million |
|
Gujarat Pipavav Port Limited
NSE:GPPL
|
India | ₹5.63 Billion |
|
Xiandai Investment Co Ltd
SHE:000900
|
China | CN¥44.46 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Cisen Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cisen Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cisen Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Cisen Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.57 Billion | -0.29% |
| 2023-12-31 | CN¥1.57 Billion | +7.68% |
| 2022-12-31 | CN¥1.46 Billion | +11.55% |
| 2021-12-31 | CN¥1.31 Billion | -4.08% |
| 2020-12-31 | CN¥1.36 Billion | +42.06% |
| 2019-12-31 | CN¥959.97 Million | -12.20% |
| 2018-12-31 | CN¥1.09 Billion | +7.45% |
| 2017-12-31 | CN¥1.02 Billion | +3.60% |
| 2016-12-31 | CN¥982.26 Million | +5.02% |
| 2015-12-31 | CN¥935.33 Million | +18.03% |
| 2014-12-31 | CN¥792.44 Million | +24.50% |
| 2013-12-31 | CN¥636.48 Million | +35.40% |
| 2012-12-31 | CN¥470.06 Million | +104.36% |
| 2011-12-31 | CN¥230.02 Million | -- |